Lung Cancer | Clinical

Key Advances in Precision Medicine in Lung Cancer

May 10, 2021

Robert Coleman, MD, FACOG, FACS, discusses key advances in precision medicine in lung cancer.

Roundtable Discussion: Finding Targets for Adjuvant NSCLC Treatment

May 10, 2021

Corey J. Langer, MD, led a peer discussion around novel targets for adjuvant non–small cell lung therapy.

Patient With RET-Mutated Lung Cancer Is Eligible for Therapy With Selpercatinib or Pralsetinib

May 07, 2021

Luis Raez, MD, Hdiscussed the case of a 59-year-old patient with RET-mutated lung cancer.

Frontline Durvalumab Plus Tremelimumab and Chemotherapy Improves OS in NSCLC

May 07, 2021

The combination of durvalumab, tremelimumab, and chemotherapy showed statistically significant and clinically meaningful overall survival benefit compared to chemotherapy alone for the first-line treatment of patients with metastatic non-small cell lung cancer.

Roundtable Discussion: Challenges in Adjuvant Treatment for Patients With NSCLC

May 04, 2021

During a Targeted Oncology Case-Based Roundtable event, Ticiana Leal, MD, discussed the case of a patient with non–small cell lung cancer with a group of peers.

Adjusting Poziotinib Dosing to Reduce Toxicity for Patients With EGFR+ or HER2 exon 20–Positive NSCLC

May 04, 2021

Xiuning Le, MD, PhD, discusses the reasoning behind splitting the dose of poziotinib dose in order to reduce adverse effects and improve efficacy for the treatment of EGFR- or HER2 exon 20–positive non–small cell lung cancer.

Data Show That PD-L1 Status Affects the Efficacy of Pembrolizumab in Non–Small Cell Lung Cancer

May 01, 2021

Ravi Salgia, MD, PhD, discussed the case of a 59-year-old patient with non–small cell lung cancer during a virtual Targeted Oncology Case-Based Roundtable event.

Oleclumab Plus Osimertinib Show Early Activity and Tolerability EGFR-Mutant NSCLC

May 01, 2021

The combination of oleclumab and osimertinib was well-tolerated and demonstrated preliminary anti-tumor activity in patients with non-small-cell lung cancer with an EGFR mutation after progression on an EGFR tyrosine kinase inhibitor.

Bordoni Compares Trials in Extensive-Stage Small Cell Lung Cancer

April 30, 2021

During a virtual Targeted Oncology Case-Based Roundtable event, Rodolfo Bordoni, MD, discussed recent clinical trials in the extensive-stage small cell lung cancer space.

LIBRETTO-001 and ARROW Trials Show Positive Data in RET Fusion–Positive Lung Cancer

April 28, 2021

Jessica Bauman, MD, reviewed data from the LIBRETTO-001 and ARROW trials which show the efficacy and safety of selpercatinib and pralsetinib for the treatment of patients with RET fusion-positive lung cancer.